The crisis over GLP-1 out-of-pocket costs deepens—it’s time for health-care leaders to step up
Wegovy, Zepbound, Saxenda, and other GLP-1 or GIP medications are needlessly out of reach for many Americans.

Apr 20, 2025 0
Apr 20, 2025 0
Apr 20, 2025 0
Apr 19, 2025 0
Apr 19, 2025 0
Apr 17, 2025 0
Apr 16, 2025 0
Feb 9, 2025 0
Feb 9, 2025 0
Feb 9, 2025 0
Feb 9, 2025 0
Apr 20, 2025 0
Apr 20, 2025 0
Apr 17, 2025 0
Apr 17, 2025 0
Apr 17, 2025 0
Apr 17, 2025 0
Apr 20, 2025 0
Apr 20, 2025 0
Apr 20, 2025 0
Apr 20, 2025 0
Apr 20, 2025 0
Apr 20, 2025 0
Apr 19, 2025 0
Apr 18, 2025 0
Apr 20, 2025 0
Apr 20, 2025 0
Apr 20, 2025 0
Apr 20, 2025 0
Apr 19, 2025 0
Mar 7, 2025 0
Apr 20, 2025 0
Apr 20, 2025 0
Apr 20, 2025 0
Apr 18, 2025 0
Apr 17, 2025 0
Apr 16, 2025 0
Apr 20, 2025 0
Apr 20, 2025 0
Apr 20, 2025 0
Apr 20, 2025 0
Apr 19, 2025 0
Apr 20, 2025 0
Apr 20, 2025 0
Apr 20, 2025 0
Apr 20, 2025 0
Apr 19, 2025 0
Apr 19, 2025 0
Apr 18, 2025 0
Apr 17, 2025 0
Apr 16, 2025 0
Apr 19, 2025 0
Apr 18, 2025 0
Apr 17, 2025 0
Apr 17, 2025 0
Apr 16, 2025 0
Apr 18, 2025 0
Apr 11, 2025 0
Or register with email
Feb 9, 2025 0
Feb 9, 2025 0
Feb 9, 2025 0
Feb 9, 2025 0
Feb 26, 2025 0
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.